Plasma amyloid‐β40/42 ratio can distinguish co‐morbid Alzheimer’s disease pathology in patients with Lewy body disease

Moeko Shinohara, Hidetomo Murakami, Yasuhiro Sakashita, Yukiko Mori, Junji Komatsu, Daiki Muramatsu, Sadao Hikishima, Kenjiro Ono · 2025

Read Plasma amyloid‐β40/42 ratio can distinguish co‐morbid Alzheimer’s disease pathology in patients with Lewy body disease by Moeko Shinohara, Hidetomo Murakami, Yasuhiro Sakashita, Yukiko Mori, Junji Komatsu, Daiki Muramatsu, Sadao Hikishima, Kenjiro Ono (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11716560.txt.

Description

Moeko Shinohara and seven co-authors published a study in 2025 on finding hidden Alzheimer's disease in patients with Lewy body disease. The two conditions often occur together, and the mix changes how illness unfolds. No blood test had yet been shown to reveal the Alzheimer's part in these patients.

The team measured two forms of amyloid in blood from patients with Lewy body disease, with and without amyloid in the brain, and from Alzheimer's patients. The ratio of the two forms was lower when brain amyloid was present and sorted the groups fairly well. A simple blood ratio might help doctors spot the hidden condition. Larger studies will need to confirm the ratio before it enters routine use.

Catalog record

CREATORMoeko Shinohara, Hidetomo Murakami, Yasuhiro Sakashita, Yukiko Mori, Junji Komatsu, Daiki Muramatsu, Sadao Hikishima, Kenjiro Ono
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE1 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11716560

Browse the full library · About the Tower of Babel